Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05361655 · ClinicalTrials.gov registry record
Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 2,888
- Enrollment target
NCT05361655 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 2,888 participants.
The verdict
NCT05361655 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 2,888 participants
- Enrollment target
Study Summary
A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Analytic Database to compare effectiveness (i.e., overall survival) of first line palbociclib + aromatase inhibitor (AI) versus AI alone treatment in postmenopausal women or men with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (MBC) in the United States clinical practices.
Interventions
- DRUG Aromatase inhibitor
- DRUG Palbociclib + an aromatase inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,888 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2021-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05361655
The ClinicalTrials.gov registry entry for NCT05361655 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,888 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aromatase inhibitor is the first listed.
NCT05361655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05361655 about?
NCT05361655 is a clinical study titled "Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor". A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Analytic Database to compare effectiveness (i.e., overall survival) of first line palbociclib + aromatase inhibitor (AI) versus AI alone treatment in postmenopausal women or men with hor...
What is the current status of trial NCT05361655?
This trial is currently completed. The enrollment target is 2,888 participants. The study started on 2021-09-01. Estimated completion is 2021-09-01.
What interventions are being tested in trial NCT05361655?
The interventions under investigation include: Aromatase inhibitor (DRUG), Palbociclib + an aromatase inhibitor (DRUG).
Who is sponsoring clinical trial NCT05361655?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.